Artelo Biosciences Stock Performance
| ARTL Stock | USD 1.71 0.05 3.01% |
The firm shows a Beta (market volatility) of -0.38, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Artelo Biosciences are expected to decrease at a much lower rate. During the bear market, Artelo Biosciences is likely to outperform the market. At this point, Artelo Biosciences has a negative expected return of -0.91%. Please make sure to confirm Artelo Biosciences' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Artelo Biosciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Artelo Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in February 2026. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
Last Split Factor 1:6 | Dividend Date 2019-06-21 | Last Split Date 2025-06-13 |
1 | Will Artelo Biosciences Inc. outperform the market - Trade Risk Assessment Free High Return Stock Watch Alerts - newser.com | 11/11/2025 |
2 | Acquisition by Favorito Tamara A of 1083 shares of Artelo Biosciences at 1.55 subject to Rule 16b-3 | 11/14/2025 |
3 | Maxim Downgrades Artelo Biosciences to Hold From Buy - MarketScreener | 11/19/2025 |
4 | 12 Health Care Stocks Moving In Mondays After-Market Session - Benzinga | 12/01/2025 |
5 | Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 Inhibit... | 12/03/2025 |
6 | Is Artelo Biosciences Inc. stock a buy in volatile markets - 2025 Investor Takeaways Comprehensive Market Scan Reports - DonanmHaber | 12/19/2025 |
7 | Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Cand... | 12/23/2025 |
8 | Is Artelo Biosciences Inc. stock a buy in volatile markets - July 2025 Technicals Growth Focused Entry Point Reports - ulpravda.ru | 01/08/2026 |
9 | Artelo Biosciences Received Notice of Noncompliance - TradingView Track All Markets | 01/16/2026 |
| Begin Period Cash Flow | 2.8 M | |
| Total Cashflows From Investing Activities | 7.8 M |
Artelo Biosciences Relative Risk vs. Return Landscape
If you would invest 388.00 in Artelo Biosciences on October 20, 2025 and sell it today you would lose (217.00) from holding Artelo Biosciences or give up 55.93% of portfolio value over 90 days. Artelo Biosciences is currently does not generate positive expected returns and assumes 8.4233% risk (volatility on return distribution) over the 90 days horizon. In different words, 75% of stocks are less volatile than Artelo, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Artelo Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Artelo Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Artelo Biosciences, and traders can use it to determine the average amount a Artelo Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1082
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ARTL |
Based on monthly moving average Artelo Biosciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Artelo Biosciences by adding Artelo Biosciences to a well-diversified portfolio.
Artelo Biosciences Fundamentals Growth
Artelo Stock prices reflect investors' perceptions of the future prospects and financial health of Artelo Biosciences, and Artelo Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Artelo Stock performance.
| Return On Equity | -4.36 | ||||
| Return On Asset | -1.36 | ||||
| Current Valuation | 2.69 M | ||||
| Shares Outstanding | 2.02 M | ||||
| Price To Earning | 16.31 X | ||||
| Price To Book | 0.50 X | ||||
| EBITDA | (10.11 M) | ||||
| Net Income | (9.83 M) | ||||
| Cash And Equivalents | 21.32 M | ||||
| Cash Per Share | 7.51 X | ||||
| Total Debt | 104 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 42.28 X | ||||
| Book Value Per Share | (0.41) X | ||||
| Cash Flow From Operations | (8.35 M) | ||||
| Earnings Per Share | (19.50) X | ||||
| Market Capitalization | 3.51 M | ||||
| Total Asset | 4.7 M | ||||
| Retained Earnings | (50.14 M) | ||||
| Working Capital | 785 K | ||||
| Current Asset | 99.89 M | ||||
| Current Liabilities | 23.67 M | ||||
About Artelo Biosciences Performance
By examining Artelo Biosciences' fundamental ratios, stakeholders can obtain critical insights into Artelo Biosciences' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Artelo Biosciences is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.33) | (3.49) | |
| Return On Capital Employed | (3.97) | (3.77) | |
| Return On Assets | (1.88) | (1.98) | |
| Return On Equity | (3.96) | (3.76) |
Things to note about Artelo Biosciences performance evaluation
Checking the ongoing alerts about Artelo Biosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Artelo Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Artelo Biosciences generated a negative expected return over the last 90 days | |
| Artelo Biosciences has high historical volatility and very poor performance | |
| Artelo Biosciences may become a speculative penny stock | |
| Artelo Biosciences has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (9.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Artelo Biosciences currently holds about 21.32 M in cash with (8.35 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.51, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Artelo Biosciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Artelo Biosciences Received Notice of Noncompliance - TradingView Track All Markets |
- Analyzing Artelo Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Artelo Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Artelo Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Artelo Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Artelo Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Artelo Biosciences' stock. These opinions can provide insight into Artelo Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Artelo Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Artelo Stock please use our How to buy in Artelo Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Artelo Biosciences. If investors know Artelo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Artelo Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Artelo Biosciences is measured differently than its book value, which is the value of Artelo that is recorded on the company's balance sheet. Investors also form their own opinion of Artelo Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Artelo Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Artelo Biosciences' market value can be influenced by many factors that don't directly affect Artelo Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Artelo Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Artelo Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Artelo Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.